Until 2019, most people assumed the cannabis plant's pharmacological story had been largely written. THC was the primary psychoactive compound. CBD was its non-psychoactive counterpart. The minor cannabinoids filled in the edges. Then a team of Italian researchers published a study in Scientific Reports announcing the discovery of two previously unknown cannabinoids in a sample of FM2 cannabis, a variety grown by the Italian government for pharmaceutical use.
One of them was THCp.
THCp, full name tetrahydrocannabiphorol, is a naturally occurring cannabinoid found in cannabis in very small concentrations. It is structurally similar to delta-9 THC, the compound responsible for cannabis's psychoactive effects, but with one significant difference: the length of its alkyl side chain.
THC has a five-carbon side chain that attaches to the CB1 receptor in the brain. THCp has a seven-carbon side chain. That extra length matters considerably for how strongly the molecule binds to the receptor.
In laboratory testing, THCp demonstrated binding affinity to CB1 receptors that was approximately 33 times higher than delta-9 THC. What this means in practical terms is that THCp appears to interact with the endocannabinoid system more potently than THC at the same dose, at least in the receptor binding studies that have been conducted.
This is worth stating with appropriate caution: binding affinity in laboratory conditions does not straightforwardly translate to a 33 times stronger high in a human consumer. The relationship between receptor binding and experienced effect is complex, and very limited human data exists on THCp specifically. The research is genuinely early-stage.
THCp occurs naturally in cannabis, but in extremely low concentrations, typically well under 0.1% by weight even in high-THC cultivars. The 2019 discovery paper reported THCp in the FM2 strain at trace amounts detectable only through advanced mass spectrometry.
This is different from how THCp appears in most consumer products. The large majority of THCp sold in the broader US market, particularly in hemp-derived products, is synthetic or semi-synthetic: produced in a laboratory by chemically converting CBD or other hemp-derived cannabinoids. This is not the same as naturally occurring THCp in licensed California cannabis.
California's licensed cannabis market operates under BCC regulations that require third-party lab testing for all products. The cannabinoid panel on a licensed California product will show THCA, delta-9 THC, CBD, CBG, and occasionally CBN. THCp does not appear on standard California COA panels, which reflects how rarely it occurs in meaningful concentrations in naturally grown cannabis.
Understanding what makes THCp distinct from regular THC requires a brief look at how cannabinoids interact with receptors.
The endocannabinoid system has two primary receptor types: CB1 receptors, concentrated in the brain and central nervous system, and CB2 receptors, concentrated in the immune system and peripheral tissues. Delta-9 THC produces its psychoactive effects primarily through CB1 receptor activation.
The potency of a cannabinoid at CB1 receptors depends partly on how well its molecular shape fits the receptor, similar to a key fitting a lock. The alkyl side chain is the part of the molecule that determines this fit. THC's five-carbon side chain produces the familiar psychoactive profile. Research has established that extending the side chain beyond five carbons generally increases binding affinity, with the seven-carbon version (THCp) showing the most pronounced effect of the natural cannabinoids identified so far.
Beyond seven carbons, the binding affinity begins to decline again, which is why THCp's seven-carbon structure appears to be a potency peak among naturally occurring variants.
Not as a labelled compound. California's licensed cannabis products display cannabinoid data from independent third-party lab analysis. Current standard COA panels test for the primary cannabinoids, THCA, delta-9 THC, CBD, CBG, and CBN, and do not specifically test for THCp.
THCp may be present in trace amounts in any full-spectrum cannabis product, as it is a naturally occurring compound in the plant. At the concentrations found in naturally grown cannabis, its contribution to the overall effect profile is difficult to isolate and not something any licensed California retailer claims or tests for specifically.
What every Smoakland product listing does show is verified THCA, delta-9 THC, and total cannabinoid percentages from independent lab testing. For consumers interested in the full cannabinoid picture, the THCA vs Delta-9 THC explainer covers how those figures relate to what you actually consume.
The 2019 discovery of THCp was significant not because it will immediately change what consumers experience from California cannabis, but because it added a previously unknown piece to the picture of how cannabis affects human physiology.
One of the standing questions in cannabis research has been why some strains produce effects more intense than their measured THC percentage would predict. THCp, present in trace amounts but highly potent at CB1 receptors, is one plausible part of that answer. Another is the entourage effect: the interaction between all cannabinoids and terpenes together producing an outcome that pure THC alone does not replicate.
The discovery also raised the question of what other rare cannabinoids remain unidentified. Cannabis contains over a hundred known cannabinoids, and analytical chemistry is still uncovering minor components that were previously too scarce to detect with older testing methods.
In the national hemp-derived cannabinoid market, THCp products are sold in states where delta-9 THC is not legal recreationally. These products use synthetic or semi-synthetic THCp derived from hemp, and they operate in a regulatory grey area that differs significantly from California's licensed cannabis system.
California consumers purchasing from licensed retailers like Smoakland are buying products regulated under California's Medicinal and Adult-Use Cannabis Regulation and Safety Act (MAUCRSA), with mandatory lab testing, compliant packaging, and traceable supply chains. The THCp product landscape in other markets carries different quality and consistency standards.
THCp (tetrahydrocannabiphorol) is a naturally occurring cannabinoid discovered in cannabis in 2019 by Italian researchers. It is structurally similar to delta-9 THC but with a seven-carbon side chain instead of five, giving it significantly higher binding affinity to CB1 receptors in laboratory studies. It occurs in trace concentrations in naturally grown cannabis, typically under 0.1% by weight.
In laboratory receptor binding studies, THCp demonstrated approximately 33 times higher CB1 binding affinity than delta-9 THC. However, binding affinity does not directly equal experiential potency in human consumers. The relationship is complex and human-specific research on THCp is limited. It appears to be significantly more potent per molecule than THC, but naturally occurring concentrations in cannabis are very low.
Yes, THCp occurs naturally in cannabis at trace concentrations. It was first identified in an Italian government-cultivated cannabis variety (FM2) in 2019 using advanced mass spectrometry. Many THCp products on the market use synthetic or semi-synthetic THCp derived from hemp, which is different from naturally occurring THCp in whole cannabis plants.
No. Standard California COA panels test for primary cannabinoids, THCA, delta-9 THC, CBD, CBG, and CBN, and do not specifically test for THCp. The concentrations at which it naturally occurs in licensed California cannabis are too small to appear on standard lab reports.
THCp was discovered and reported in December 2019 by a team of Italian researchers led by Cinzia Citti and Giuseppe Cannazza, published in the journal Scientific Reports. The same study also identified a CBD analogue called CBDp with a similar extended side chain structure.
This content is for informational and educational purposes only and is intended for adults 21+ in jurisdictions where cannabis is legal. It does not constitute medical advice. Never consume cannabis before driving. Smoakland complies with all applicable California cannabis regulations. License #C9-0000843-LIC, C9-0000655-LIC, C9-0000174-LIC.